British journal of pharmacology
Imperatorin ameliorates metabolic dysfunction-associated fatty liver disease through modulating Suv39h1/Fabps/Cept1 signalling pathway.
Yi Sun, Changyuan Wang, Yang Wang, Ru Hao, Lu Liu, Yue Jin, Huijun Sun
Published: 202510.1111/bph.70210
Abstract
BACKGROUND AND PURPOSE: Metabolic dysfunction associated fatty liver disease (MAFLD) is a leading cause of irreversible liver fibrosis and finally liver cancer. Imperatorin was reported to be effective for liver injury and fibrosis, but its effects a…
Preview only. Read the full abstract at the source